Hematology/Oncology

Top Story

Renal transplant recipients at greater risk for melanoma

July 27, 2017

Renal transplant recipients had a greater risk than the general population for melanoma, according to recently published study results in JAMA Dermatology.

Researchers used the United States Renal Data System (USRDS) database to study 105,174 renal transplant recipients (mean age, 49.6 years; 60.7% male) between 2004 and 2012.

Meeting News

Guest Commentary: Debu Tripathy, MD, reviews highlights in breast cancer from ASCO 2017

July 27, 2017
In this guest commentary, Debu Tripathy, MD, professor and chair of the department of breast medical oncology at The University of Texas MD Anderson Cancer Center and a

AstraZeneca, Merck to collaborate on olaparib development

July 27, 2017
AstraZeneca and Merck entered a global strategic collaboration to develop and commercialize olaparib to treat multiple malignancies. Olaparib (Lynparza, AstraZeneca)…
In the Journals

Women less likely to undergo immediate breast reconstruction at safety net hospitals

July 27, 2017
Women undergoing mastectomies at safety net hospitals were significantly less likely to undergo immediate breast reconstruction than women at non-safety net hospitals…
In the Journals

Patient navigator program at barbershops boosts colon cancer screening in black men

July 27, 2017
A community-based, preclinical patient navigator program that recruited black men at local barbershops doubled the rate of colorectal cancer screening in this high-risk…
More Headlines »
CME

Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

This activity is supported by an educational grant from Bristol-Myers Squibb.

Incidence rates of melanoma in the United States continue to rise, with an estimated 87,110 new cases being diagnosed…
More »
Video
Meeting News

VIDEO: Adam Brufsky, MD, PhD, discusses results of MONARCH-2, PALOMA-1 trials

June 23, 2017
More »
Resource Centers
Biosimilars in the US

Biosimilars in the US

CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement